Millennium Management LLC purchased a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 142,209 shares of the company's stock, valued at approximately $462,000. Millennium Management LLC owned about 0.21% of Inhibikase Therapeutics at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Northern Trust Corp purchased a new stake in Inhibikase Therapeutics during the fourth quarter worth approximately $208,000. Stifel Financial Corp purchased a new position in Inhibikase Therapeutics in the 4th quarter valued at $43,000. Blackstone Inc. purchased a new position in Inhibikase Therapeutics during the 4th quarter worth $6,730,000. Nantahala Capital Management LLC acquired a new stake in shares of Inhibikase Therapeutics in the 4th quarter worth $7,118,000. Finally, Barclays PLC purchased a new stake in shares of Inhibikase Therapeutics in the fourth quarter valued at about $273,000. Hedge funds and other institutional investors own 3.81% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "neutral" rating on shares of Inhibikase Therapeutics in a research report on Friday, March 28th.
View Our Latest Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Stock Performance
NYSE IKT traded down $0.05 during trading hours on Friday, reaching $1.86. The company's stock had a trading volume of 92,001 shares, compared to its average volume of 237,791. The company's 50-day moving average is $2.00 and its two-hundred day moving average is $2.43. Inhibikase Therapeutics, Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $4.20. The stock has a market cap of $138.28 million, a PE ratio of -0.70 and a beta of 0.94.
Inhibikase Therapeutics Company Profile
(
Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
See Also
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
